Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general and admin

Change in fair value of acquisition consideration

Restructuring costs

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Twist Bioscience Corp

Twist Bioscience Corp. engages in the development of a proprietary semiconductor-based synthetic DNA manufacturing process. Its products include genes, oligo pools, Next Generation Sequencing (NGS), variant libraries, synthetic controls, antibody discovery, and SARS-CoV-2 Tools. It operates through the following geographical segments: Americas, EMEA, and APAC. The Americas segment consists of the United States of America, Canada, Mexico, and South America. The EMEA segment includes Europe, Middle East, and Africa. The APAC segment consists of Japan, China, South Korea, India, Singapore, Malaysia, and Australia. The company was founded by William Marine Banyai, Emily Marine Leproust, and Bill James Peck on February 4, 2013 and is headquartered in San Francisco, CA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Twist Bioscience Corp meets Q1 expectations, eyes growth opportunities

Twist Bioscience Corp's Q1 performance met or exceeded expectations across key revenue segments, with a focus on expanding customer base and improving turnaround times.
While facing challenges such as COVID impact on China sales and margin dips due to fixed costs, the company aims for revenue growth and improved margins through strategic execution.
The company's strengths lie in strong gross margins, record bookings in NGS, and efforts towards DNA data storage alliances, positioning for future growth and innovation.
Opportunities include continued customer expansion, Fast Gene market development, and revenue growth driven by NGS and SynBio performance, amidst a value-based pricing strategy.

Twist Bioscience Corp achieves $60.2M revenue in Q2 2023

Twist Bioscience Corp's Q2 2023 earnings call highlighted strong revenue growth, cost reduction efforts, and a focus on achieving profitability. The company is navigating challenges in the biopharma sector while leveraging strengths in technology and sales execution for future growth.

Twist Bioscience Corp reports record Q3 revenue, focuses on growth

Twist Bioscience Corp delivered a strong performance in Q3, with record revenue and strategic product launches driving growth across key segments.
While facing challenges in biopharma revenue and commercial execution, the company is focused on expansion, talent acquisition, and cost management to drive future growth.
With a clear focus on innovation, market expansion, and achieving profitability milestones, Twist Bioscience Corp is well-positioned for future success and market leadership.
The company's strengths in SynBio products, strategic market positioning, and stable funding outlook underscore its potential for sustained growth and value creation.

Twist Bioscience Corp reports robust revenue growth and eyes profitability

Twist Bioscience Corp's Q4 2023 earnings call highlighted strong revenue growth, operational efficiency, and a solid financial position.
The company faces challenges in managing expenses and achieving profitability but sees opportunities in revenue growth and market expansion.
By leveraging strengths in product launches, customer relationships, and revenue growth, Twist Bioscience aims for continued success and margin expansion in fiscal 2024.

Twist Bioscience Corp excels in Q1 2024, focuses on growth

Twist Bioscience Corp's Q1 2024 earnings call highlighted robust revenue growth, margin expansion, and strategic focus on operational efficiency. The company's emphasis on customer needs, premium pricing, and cost efficiency positions it well for future growth and profitability.

Twist Bioscience reports robust Q2 revenue growth and margin targets

Twist Bioscience Corp delivered strong revenue growth and aims for margin improvement, driven by successful product lines and strategic initiatives.
While facing challenges in managing expenses and achieving profitability, the company is well-positioned to leverage market opportunities and regulatory advantages.
With a focus on innovation, market expansion, and margin growth, Twist is poised for continued success and competitive growth in the biopharma sector.
Navigating operational challenges and seizing growth opportunities will be crucial for Twist Bioscience to achieve its financial targets and sustain market leadership.

Twist Bioscience Corp reports robust Q3 revenue growth and profitability outlook

Twist Bioscience Corp delivered strong revenue growth and operational performance in Q3 2024, driven by robust NGS and biopharma revenue streams.
While facing challenges in achieving profitability targets, the company's focus on margin improvement and capacity expansion positions it for future growth.
Guidance for fiscal 2024 indicates promising revenue growth, highlighting opportunities for sustained expansion and enhanced financial performance.

Twist Bioscience Corp reports record revenue and aims for profitability

Twist Bioscience Corp delivered strong financial performance, with record revenue and margin growth driven by key product segments and operational efficiencies.
The company's focus on achieving adjusted EBITDA profitability and cash flow positivity, along with robust fiscal 2025 guidance, signals a path towards sustainable growth.
While challenges like cost management and market competition persist, opportunities in market traction, revenue diversification, and innovation position the company for continued success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Twist Bioscience Corp. engages in the development of a proprietary semiconductor-based synthetic DNA manufacturing process. It operates through the following geographical segments: Americas, EMEA, and APAC. The Americas segment consists of the United States of America, Canada, Mexico, and South America. The EMEA segment includes Europe, Middle East, and Africa. The APAC segment focuses on Japan, China, South Korea, India, Singapore, Malaysia, and Australia. The company was founded by William Marine Banyai, Emily Marine Leproust, and Bill James Peck in 2013 and is headquartered in San Francisco, CA.

Twist Bioscience (TWST) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Twist Bioscience (TWST) Expected to Beat Earnings Estimates: Should You Buy?

SOUTH SAN FRANCISCO, Calif. & TAMPA, Fla.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and Aster Insights, a bioinformatics company with the most advanced, direct-patient, lifetime-consented clinicogenomics data to accelerate oncology discovery research, today announced the availability of the AsterExome panel, which can simultaneously enable whole exome seque.

Twist Bioscience and Aster Insights Partner on Launch of Next Generation Oncology Panel for Cancer Research

Avalo Therapeutics

Oric Pharmaceuticals

Exact Sciences

INmune Bio Inc

Synlogic

Tenaya Therapeutic

Personalized medicine stocks are hot right now. This form of medicine based on the particular genes, proteins, and other substances in a person's body.

The 7 Best Biotech Stocks for Personalized Medicine Investors

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced a collaboration with Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura., “Astellas”), by which Astellas will license a suite of Twist's VHH antibody libraries to be used by Astellas for drug discovery and development.

Twist Bioscience Enters into Third Collaboration with Astellas to Support Antibody Discovery for Immunotherapies

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the launch of Twist T-cell Receptor (TCR), and Twist chimeric antigen receptor (CAR) Libraries. These new libraries provide researchers with the ability to rapidly create custom libraries that can enable the identification and development of next generation cell therapies.

Twist Bioscience Launches TCR and CAR Libraries to Enable the Development of Cell Therapies

SOUTH SAN FRANCISCO--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it will issue its financial results for the fiscal 2023 second quarter ended March 31, 2023, before the opening of the market on Friday, May 5, 2023. The company plans to hold a conference call and live audio webcast for analysts and investors at 8:00 a.m.

Twist Bioscience to Report Fiscal 2023 Second Quarter Financial Results on Friday, May 5, 2023

Illumina

Microsoft

Western Digital

SAN DIEGO--(BUSINESS WIRE)--The DNA Data Storage Alliance, a SNIA Technology Affiliate, formed in 2020 by Illumina, Inc. (NASDAQ: ILMN), Microsoft (Nasdaq: MSFT), Twist Bioscience Corporation (NASDAQ: TWST) and Western Digital (NASDAQ: WDC) to create and promote an interoperable storage ecosystem based on DNA as a data storage medium, today announced the appointments of CATALOG Technologies and Quantum Corporation to the governing board of the Alliance.

DNA Data Storage Alliance Announces Board Appointments

NEW YORK--(BUSINESS WIRE)-- #A--Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Twist Bioscience Corp (NASDAQ: TWST) on behalf of long-term stockholders following a class action complaint that was filed against Twist on December 12, 2022 with a Class Period from December 13, 2019 to November 14, 2022. Our investigation concerns whether the board of directors of Twist have breached their fiduciary duties to the company.

TWIST ALERT: Bragar Eagel & Squire, P.C. is Investigating Twist Bioscience Corp on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced an integrated offering of antibody discovery services available to customers. The offering combines Twist Biopharma's synthetic libraries and AI machine learning with an in vivo immunization approach gained through the acquisition of Abveris, also known as Twist Boston.

Twist Bioscience Announces Robust Antibody Discovery Services Integrating In Vivo, In Vitro and In Silico Approaches

Twist Bioscience (TWST) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

Twist Bioscience (TWST) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

Amyris

Ginkgo Bioworks Holdings

Since the biotech bonanza of the pandemic era, many biotech stocks have rocketed up and then down in price. Ginkgo Bioworks (NYSE: DNA ), Twist Bioscience (NASDAQ: TWST ), and Amyris (NASDAQ: AMRS ) all fell more than 75% from peak to trough, and may still have farther to fall.

The Next Big Disruptors? 3 Biotech Stocks Making Headlines.

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today published on the successful discovery of alpaca-derived VHH antibodies using a disruptive, function-forward in vivo discovery workflow developed by Abveris, also known as Twist Boston, on the Beacon optofluidic platform.

Twist Bioscience Publishes Data on VHH Single Domain Antibody Discovery Using New Methodology on Optofluidic Platform

Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Twist To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - February 10, 2023) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Twist Bioscience Corporation ("Twist" or the "Company") (NASDAQ: TWST) and reminds investors of the February 10, 2023 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Twist Shareholder Action Reminder

NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Twist Bioscience Corporation (NASDAQ: TWST) between December 13, 2019 and November 14, 2022, both dates inclusive (the “Class Period”), of the important February 10, 2023 lead plaintiff deadline.

TWST FINAL DEADLINE TODAY: ROSEN, NATIONAL TRIAL LAWYERS, Encourages Twist Bioscience Corporation Investors to Secure Counsel Before Important February 10 Deadline in Securities Class Action – TWST

Los Angeles, California--(Newsfile Corp. - February 10, 2023) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Twist Bioscience Corporation ("Twist" or "the Company") (NASDAQ: TWST) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

DEADLINE TOMORROW: The Schall Law Firm Encourages Investors in Twist Bioscience Corporation with Losses of $100,000 to Contact the Firm

NEW YORK , Feb. 10, 2023 /PRNewswire/ -- Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Twist Bioscience Corporation (NASDAQ: TWST). To receive updates on the lawsuit, fill out the form: https://claimyourloss.com/securities/twist-bioscience-corporation-loss-submission-form/?id=36400&from=4 This lawsuit is on behalf of a class of all persons and entities who purchased or otherwise acquired Twist common stock between December 13, 2019 and November 14, 2022, inclusive.

TWST SHAREHOLDER ALERT: Jakubowitz Law Reminds Twist Shareholders of a Lead Plaintiff Deadline of February 10, 2023

LOS ANGELES, CA / ACCESSWIRE / February 9, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Twist Bioscience Corporation ("Twist" or "the Company") (NASDAQ:TWST) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between December 13, 2019 and November 14, 2022, inclusive (the ''Class Period''), are encouraged to contact the firm before February 10, 2023.

FINAL DEADLINE TOMORROW: The Schall Law Firm Encourages Investors in Twist Bioscience Corporation with Losses of $100,000 to Contact the Firm

New York, New York--(Newsfile Corp. - February 9, 2023) - Levi & Korsinsky, LLP notifies investors in Twist Bioscience Corporation ("Twist" or the "Company") (NASDAQ: TWST) of a class action securities lawsuit.The lawsuit on behalf of Twist investors has been commenced in the the United States District Court for the Northern District of California.

TWST LAWSUIT ALERT: Levi & Korsinsky Notifies Twist Bioscience Corporation Investors of a Class Action Lawsuit and Upcoming Deadline

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz reminds investors of the upcoming February 10, 2023 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who acquired Twist Bioscience Corporation (“Twist” or the “Company”) (NASDAQ: TWST) common stock between December 13, 2019 and November 14, 2022, inclusive (the “Class Period”). If you are a shareholder who suffered a loss, click here to participate.

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Twist Bioscience Corporation (TWST)

Los Angeles, California--(Newsfile Corp. - February 9, 2023) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Twist Bioscience Corporation ("Twist" or "the Company") (NASDAQ: TWST) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

DEADLINE FRIDAY ALERT: The Schall Law Firm Encourages Investors in Twist Bioscience Corporation with Losses of $100,000 to Contact the Firm

RADNOR, Pa. , Feb. 8, 2023 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP informs investors that the firm has filed a securities class action lawsuit against Twist Bioscience Corporation ("Twist") (NASDAQ: TWST) on behalf of investors who purchased or acquired Twist common stock between December 13, 2019 and November 14, 2022 , inclusive (the "Class Period").

Twist Bioscience Deadline Approaching: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Twist Bioscience Corporation of Deadline in Securities Fraud Class Action Lawsuit

New York, New York--(Newsfile Corp. - February 8, 2023) - Levi & Korsinsky, LLP notifies investors in Twist Bioscience Corporation ("Twist" or the "Company") (NASDAQ: TWST) of a class action securities lawsuit.The lawsuit on behalf of Twist investors has been commenced in the the United States District Court for the Northern District of California.

Twist Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before February 10, 2023 to Discuss Your Rights - TWST

San Francisco, California--(Newsfile Corp. - February 8, 2023) - Hagens Berman urges Twist Bioscience Corporation (NASDAQ: TWST) investors who suffered significant losses to submit your losses now.Class Period: Dec. 13, 2019 - Nov. 14, 2022Lead Plaintiff Deadline: Feb. 10, 2023Visit: www.hbsslaw.com/investor-fraud/TWSTContact An Attorney Now: TWST@hbsslaw.com844-916-0895Twist Bioscience Corporation (NASDAQ: TWST) Securities Fraud Class Action: The litigation challenges Twist's statements regarding its proprietary technology related t

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Twist Bioscience (TWST) Investors with Losses to Contact Firm's Attorneys Before Feb. 10th Deadline in Securities Fraud Class Action

Twist Bioscience (TWST) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Twist Bioscience (TWST) Upgraded to Buy: Here's Why

LOS ANGELES , Feb. 8, 2023 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Twist Bioscience Corporation ("Twist" or the "Company") (NASDAQ: TWST).

News for Twist Bioscience Corp Stock (TWST)